Intellia Therapeutics (NTLA) Stock News
$NTLA · NASDAQ · 4 stories in 30 days$11.20
1D −1.23%1W −3.72%1M +0.34%
BORSA has published 4 stories on Intellia Therapeutics (NTLA) in the past 30 days. BORSA’s news read on NTLA is bullish at 64/100, unchanged over 24 hours, based on 1 company event over the past 7 days. NTLA last closed at $11.91 on Oct 13, down 3.72% over five sessions and up 0.34% over the past month. Intellia Therapeutics’ next earnings report is scheduled for Thursday, Nov 5.
The wire on $NTLA
newest first · updated · direct subject stories onlyIntellia Therapeutics appoints Jing L. Marantz as chief medical officer
Intellia Therapeutics named Jing L. Marantz as EVP and chief medical officer, effective Oct. 26. Marantz, former CMO of Scholar Rock, brings rare disease approval experience as the company nears commercialization of its first CRISPR gene editing product and advances Phase 3 trials in transthyretin amyloidosis.
neutral 50 · impact 30
